NCT04147819 - A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

August 21, 2023

Study Completion Date

September 26, 2023

Conditions

Cancers With HER2 Expression

Interventions

DRUG

BAY2701439

Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).

DRUG

BAY2701439

Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).

Trial Locations (6)

10022

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins Hospital/Health System, Baltimore

63110

Washington University School of Medicine, St Louis

77030

University of Texas MD Anderson Cancer Center, Houston

SO16 6YD

Southampton General Hospital, Southampton

SM2 5PT

Royal Marsden NHS Trust (Surrey), Sutton